Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study
Authors:
- Antonio AlcarazAAAntonio Alcaraz
- Mauro GacciMauro Gacci
- Vincenzo FicarraVFVincenzo Ficarra
- José Medina-PoloJMJosé Medina-Polo
- Andrea SaloniaASAndrea Salonia
- Jesús M. Fernández-GómezJFJesús M. Fernández-Gómez
- Alexandru CiudinACAlexandru Ciudin
- David Castro-DíazDCDavid Castro-Díaz
- Alfredo Rodríguez-AntolínARAlfredo Rodríguez-Antolín
- Joaquín Carballido-RodríguezJCJoaquín Carballido-Rodríguez
- José M. Cózar-OlmoJCJosé M. Cózar-Olmo
- Santiago Búcar-TerradesSBSantiago Búcar-Terrades
Open Access
- 12 February 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (4) , 967
Abstract
We investigated changes in symptoms and quality of life (QoL) in men with moderate-to-severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) receiving the hexanic extract of Serenoa repens (HESr) and compared results with a matched group on watchful waiting (WW). Data was from a real-world, open-label, prospective, multicenter study. This sub-group analysis included patients with moderate-to-severe symptoms receiving either the HESr 320 mg/daily for six months (HESr) or who remained untreated for LUTS/BPH (WW). Changes in urinary symptoms and QoL were measured by IPSS and BII questionnaires. Two statistical approaches (iterative matching and propensity score pairing) were used to maximize between-group comparability at baseline. Tolerability was assessed in the HESr group. After iterative matching, data for analysis was available for 783 patients (102 WW, 681 HESr). IPSS scores improved by a mean (SD) of 3.8 (4.4) points in the HESr group and by 2.2 (4.5) points in the WW group (p = 0.002). Changes in BII score were 1.8 (2.4) points and 1.0 (2.2) points, respectively (p < 0.001). Three patients (0.9%) treated with the HESr reported mild adverse effects. Moderate-severe LUTS/BPH patients treated for six months with the HESr showed greater improvements in symptoms and QoL than matched patients on WW, with a very low rate of adverse effects.Keywords
This publication has 26 references indexed in Scilit:
- Impact of Lower Urinary Tract Symptoms and Depression on Health-Related Quality of Life in Older AdultsInternational Neurourology Journal, 2012
- Effect of Increasing Doses of Saw Palmetto Extract on Lower Urinary Tract SymptomsJAMA, 2011
- The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health‐related quality of life, anxiety and depression: EpiLUTSBJU International, 2009
- Effect of dutasteride, tamsulosin and the combination on patient‐reported quality of life and treatment satisfaction in men with moderate‐to‐severe benign prostatic hyperplasia: 2‐year data from the CombAT trialBJU International, 2009
- The natural history of benign prostatic hyperplasiaBJU International, 2006
- Saw Palmetto for Benign Prostatic HyperplasiaNew England Journal of Medicine, 2006
- The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic HyperplasiaNew England Journal of Medicine, 2003
- Symptomatic Benign Prostate Hyperplasia: Impact on Partners’ Quality of LifeEuropean Urology, 2002
- Benign Prostatic Hyperplasia Specific Health Status Measures in Clinical Research: How Much Change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is Perceptible to Patients?Journal of Urology, 1995
- IMPROVEMENT OF MEDICATION COMPLIANCE IN UNCONTROLLED HYPERTENSIONThe Lancet, 1976